Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours

Inclusion Criteria: * Histologically proven adenocarcinoma or squamous cell carcinoma of oesophagus, O-G junction and stomach, not amenable to surgical resection. * Bidimensionally measurable disease, or unidimensional measurable disease assessable by CT scanning, not within previously irradiated areas. * Patients with progressive disease during previous chemotherapy treatment or within three months of stopping treatment. * At least one previous chemotherapy regimen, given within 3 months prior to inclusion in this study. * No previous exposure to irinotecan. * Adequate bone marrow function with platelets \>100 X 109/L; WBC \> 3 X 109/L; Neutrophils \> 1.5 X 109/L at the time of study entry. * Satisfactory renal function. Creatinine clearance (measured by Cockcroft and Gault) \>50ml/min and Cr \<135. * Satisfactory liver function: * In the absence of liver metastases: Bilirubin \< 1.25N (N=upper limit of normal range) Hepatic transaminases \< 2.5N Prothrombin time \< 1.5N * In the presence of liver metastases: Bilirubin \< 1.5N Hepatic transaminases \< 5N Prothrombin time \< 1.5N * No uncontrolled medical condition * No previous malignant disease except for non-melanotic skin cancer or in-situ carcinoma of the uterine cervix. * ECOG performance status of 0, 1 or 2. * Predicted life expectancy of \> 3 months. * Adequate contraceptive precautions * Informed written consent Exclusion Criteria: * Medical or psychiatric conditions resulting in inability of patient to give written consent. * ECOG Performance status \>2 * Intracerebral metastases or meningeal carcinomatosis * Unresolved bowel obstruction * Creatinine clearance \<50ml/min, Cr \>135 * Uncontrolled angina pectoris, heart failure (New York heart classification 3 or 4). * Pregnancy/lactation * Previous malignancy other than adequately treated basal cell carcinoma of the skin or cervical carcinoma in situ.